AU2002210800A1 - Pyrimidine-2,4,6-trione metalloproteinase inhibitors - Google Patents

Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Info

Publication number
AU2002210800A1
AU2002210800A1 AU2002210800A AU1080002A AU2002210800A1 AU 2002210800 A1 AU2002210800 A1 AU 2002210800A1 AU 2002210800 A AU2002210800 A AU 2002210800A AU 1080002 A AU1080002 A AU 1080002A AU 2002210800 A1 AU2002210800 A1 AU 2002210800A1
Authority
AU
Australia
Prior art keywords
alkyl
phenoxy
group
independently selected
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002210800A
Other languages
English (en)
Inventor
Mark Carl Noe
Lawrence Alan Reiter
Martin James Wythes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU2002210800A1 publication Critical patent/AU2002210800A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002210800A 2000-10-26 2001-10-17 Pyrimidine-2,4,6-trione metalloproteinase inhibitors Abandoned AU2002210800A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24331400P 2000-10-26 2000-10-26
US60/243,314 2000-10-26
PCT/IB2001/001953 WO2002034726A2 (en) 2000-10-26 2001-10-17 Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
AU2002210800A1 true AU2002210800A1 (en) 2002-05-06

Family

ID=36950891

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002210800A Abandoned AU2002210800A1 (en) 2000-10-26 2001-10-17 Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Country Status (36)

Country Link
US (2) US6706723B2 (de)
EP (1) EP1332136A2 (de)
JP (1) JP2004512327A (de)
KR (1) KR20030061825A (de)
CN (1) CN1714084A (de)
AP (1) AP2001002319A0 (de)
AR (1) AR035362A1 (de)
AU (1) AU2002210800A1 (de)
BG (1) BG107651A (de)
BR (1) BR0114917A (de)
CA (1) CA2425280A1 (de)
CR (1) CR6939A (de)
CZ (1) CZ20031069A3 (de)
EA (1) EA200300409A1 (de)
EC (1) ECSP034568A (de)
EE (1) EE200300195A (de)
GT (1) GT200100214A (de)
HN (1) HN2001000243A (de)
HR (1) HRP20030331A2 (de)
HU (1) HUP0302337A3 (de)
IL (1) IL154946A0 (de)
IS (1) IS6749A (de)
MA (1) MA26956A1 (de)
MX (1) MXPA03003734A (de)
NO (1) NO20031852L (de)
NZ (1) NZ524774A (de)
OA (1) OA12528A (de)
PA (1) PA8531501A1 (de)
PE (1) PE20020585A1 (de)
PL (1) PL362919A1 (de)
SK (1) SK4872003A3 (de)
SV (1) SV2003000704A (de)
TN (1) TNSN01150A1 (de)
UY (1) UY26981A1 (de)
WO (1) WO2002034726A2 (de)
ZA (1) ZA200302192B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4688301A (en) * 2000-04-11 2001-10-23 Sankyo Co Stabilized pharmaceutical compositions containing calcium channel blockers
JP2004512327A (ja) * 2000-10-26 2004-04-22 ファイザー・プロダクツ・インク ピリミジン−２，４，６−トリオン・メタロプロテイナーゼ阻害剤
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
DOP2002000328A (es) 2001-02-14 2003-08-30 Warner Lambert Co Pirimidinas inhibidoras de metaloproteinasas de matriz
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
BR0207865A (pt) 2001-02-14 2004-03-23 Warner Lambert Co Benzotiadiazinas inibidores de metaloproteinases de matriz
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
BR0213233A (pt) 2001-10-12 2005-01-04 Warner Lambert Co Alcinos inibidores de metaloproteinase de matriz
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
WO2003053940A1 (en) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
AU2002357312A1 (en) * 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
CA2483500A1 (en) * 2002-04-26 2003-11-06 Pfizer Products Inc. Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
AU2003219410A1 (en) 2002-04-26 2003-11-10 Pfizer Products Inc. Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
NI200300045A (es) * 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
WO2003091258A1 (en) * 2002-04-26 2003-11-06 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
AU2003249477A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003249531A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014868A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
BR0313459A (pt) 2002-08-13 2005-06-21 Warner Lambert Co Derivados monocìclicos como inibidores de metaloproteinases de matriz
AU2003253150A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
WO2004084903A1 (en) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment of chronic wounds
EP1613269B1 (de) 2003-04-04 2015-02-25 Incyte Corporation Zusammensetzungen, verfahren und kits in zusammenhang mit her-2 spaltung
EP1737464B1 (de) * 2004-04-01 2008-07-23 F. Hoffmann-La Roche AG Verwendung von trioxopyrimidin zur behandlung und prävention von entzündlichen erkrankungen der bronchien
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
US20120046309A1 (en) 2009-05-05 2012-02-23 Northwestern University Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
RU2400233C1 (ru) 2009-07-07 2010-09-27 Общество с ограниченной ответственностью "Вирфарм" Способ лечения заболеваний печени различного генеза
KR101301533B1 (ko) * 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
SG193454A1 (en) 2011-03-14 2013-10-30 Boehringer Ingelheim Int Benzodioxane inhibitors of leukotriene production
WO2013012844A1 (en) * 2011-07-19 2013-01-24 Boehringer Ingelheim International Gmbh Arylpyrazole ethers as inhibitors of leukotriene a4 hydrolase
US8946203B2 (en) 2012-03-06 2015-02-03 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
TW201350475A (zh) 2012-03-06 2013-12-16 Boehringer Ingelheim Int 用於組合療法之白三烯素生成之苯并二噁烷抑制劑
JP6256467B2 (ja) 2012-07-17 2018-01-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成を阻害するピラゾール誘導体
US9433623B2 (en) * 2012-09-14 2016-09-06 Elizabeth LEVINA Medicinal drug with activity against gram positive bacteria, mycobacteria and fungi
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
EP3022193B1 (de) 2013-07-15 2017-04-26 Boehringer Ingelheim International GmbH Hemmer der leukotrienproduktion
JP2016523982A (ja) 2013-07-15 2016-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成の阻害剤
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
IL315313A (en) * 2018-08-24 2024-10-01 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JP2002504916A (ja) * 1997-06-21 2002-02-12 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6265578B1 (en) * 1999-02-12 2001-07-24 Hoffmann-La Roche Inc. Pyrimidine-2,4,6-triones
HN2000000137A (es) * 1999-08-12 2001-02-02 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
JP2004512327A (ja) * 2000-10-26 2004-04-22 ファイザー・プロダクツ・インク ピリミジン−２，４，６−トリオン・メタロプロテイナーゼ阻害剤

Also Published As

Publication number Publication date
CZ20031069A3 (cs) 2004-05-12
CN1714084A (zh) 2005-12-28
PA8531501A1 (es) 2003-06-30
WO2002034726A9 (en) 2003-03-06
CA2425280A1 (en) 2002-05-02
IS6749A (is) 2003-03-17
US6706723B2 (en) 2004-03-16
EA200300409A1 (ru) 2003-08-28
OA12528A (en) 2006-06-02
HUP0302337A3 (en) 2004-01-28
ECSP034568A (es) 2003-06-25
EE200300195A (et) 2003-10-15
EP1332136A2 (de) 2003-08-06
WO2002034726A3 (en) 2002-10-17
PL362919A1 (en) 2004-11-02
BR0114917A (pt) 2003-07-01
CR6939A (es) 2003-11-25
MA26956A1 (fr) 2004-12-20
AP2001002319A0 (en) 2001-12-31
WO2002034726A2 (en) 2002-05-02
HN2001000243A (es) 2002-11-07
JP2004512327A (ja) 2004-04-22
NO20031852D0 (no) 2003-04-24
NO20031852L (no) 2003-06-23
HUP0302337A2 (hu) 2003-10-28
BG107651A (bg) 2003-12-31
SK4872003A3 (en) 2004-08-03
PE20020585A1 (es) 2002-07-06
MXPA03003734A (es) 2003-07-28
TNSN01150A1 (fr) 2005-11-10
NZ524774A (en) 2004-09-24
KR20030061825A (ko) 2003-07-22
HRP20030331A2 (en) 2003-06-30
SV2003000704A (es) 2003-01-13
GT200100214A (es) 2002-07-03
ZA200302192B (en) 2004-05-05
US20050107414A1 (en) 2005-05-19
UY26981A1 (es) 2002-06-20
IL154946A0 (en) 2003-10-31
AR035362A1 (es) 2004-05-12
US20020132822A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
US6706723B2 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
US6919332B2 (en) N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
US6841671B2 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
EP1501833B1 (de) N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren
EP1501834B1 (de) Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
AU2002210813A1 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
EP1501515B1 (de) Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application